OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, has secured £1.8M in seed funding, led by Ahren Innovation Capital and with additional investment from Empirical Ventures, Kadmos Capital and Panacea Investment Group. The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the Company's in-house target discovery program and establishing new strategic partnerships with leading pharma and biotech companies.

Chesham-based startup, Flomark Ltd, has secured a £150,000 investment from British Design Fund (BDF) and £150,000 from Imperial College Enterprise Fund (ICEF) as part of a broader funding round, as it looks to accelerate the development of its pioneering solutions aimed at making IV drips safer for patients.

Marissa Krummrich, Investment Manager at b2ventures, explains the thinking behind leading Kiin Bio's $2.2m pre-seed round, with co-investment from Heartfelt, rule30 and angel investors. 

A pioneering Scottish technology that could dramatically speed up the development of life-saving cancer treatments has secured a £750,000 seed investment.  ScreenIn3D, a spin-out of the University of Strathclyde, has developed a groundbreaking "lab-on-a-chip" system that allows drug developers to test dozens of cancer therapies on tiny patient-derived tumour samples - offering a faster, easier and more accurate alternative to animal testing.

Finland: Medtech startup AIATELLA has secured €2 million in funding to accelerate the development and scaling of its AI-powered cardiovascular imaging technology. The funding will help the company conduct clinical trials and develop its ultrasound-based preventative screening, which detects and quantifies carotid artery narrowing in minutes. The round was led by Helsinki-based Nordic Science Investments, with Specialist VC, Harjavalta Ventures, Business Finland, and a syndicate of angel investors also joining the round.

MindSpire, the neurotech start-up dedicated to helping people regulate stress and unlock peak performance, has raised £850,000 in pre-seed funding. This investment will support the launch of MindSpire's first device: SONA^TM, a medical-grade wearable that delivers precision-coded electrical pulses to the vagus nerve, activating brain circuits for calm, focus and enhanced learning.

The round was led by SFC Capital, with participation from SyndicateRoom and non-dilutive innovation funding secured via Innovate UK's Investor Partnership Programme. The £850,000 investment will enable MindSpire, based at the London Institute for Healthcare Engineering (LIHE), to complete the development and launch of SONA^TM.

Hampshire based startup, Zeus Sleep, has secured a £150,000 investment from British Design Fund to help accelerate the development of its groundbreaking solutions designed to alleviate the symptoms of snoring and sleep apnoea.

Bioniq, which is renowned for its personalized nutritional supplements based on blood biomarker data, has signed up football star Diogo Dalot, right-back for Manchester United and the Portugal national team, as an investor, contributing over €1 million.

Dalot joins the global football icon Cristiano Ronaldo, who became a major investor in 2024, and brought Bioniq's total valuation to $82 million. Dalot's investment marks another milestone in Bioniq's mission to make personalized health accessible to athletes and everyday individuals worldwide.

UK agritech startup Elaniti has closed its recent funding round with participation from early-stage biotech investor biotope by VIB, Planetary Impact Ventures and Paulig Group's CVC arm, PINC.

Healsgood, the pioneering healthtech company behind Flexzo AI, has successfully closed a £1.5 million funding round to revolutionise staffing and operational efficiency across the NHS. The oversubscribed round, led by Fuel Ventures, signifies strong investor confidence in Healsgood's vision of dramatically reducing patient waiting times and NHS service delivery failures across the UK.

Eventum Orthopaedics, a UK medtech company whose device could revolutionise knee replacement surgery has raised a further £3.8m from NPIF II - Mercia Equity Finance, which is managed by Mercia Ventures as part of the Northern Powerhouse Investment Fund II (NPIF II), Mercia’s EIS funds and private investors including leading surgeons.

Eventum's QuadSense device helps surgeons to precisely cut and place the kneecap in total knee replacements. Currently over 2 million patients a year have knee replacements globally, yet around 20% are not fully satisfied with the outcome. Eventum believes the key to improving success rates is the position of the kneecap, which plays a crucial role in the knee's function.

Reactwise has secured $3.4 million in pre-seed funding, including a competitive Innovate UK grant, to enable AI-driven robotic laboratories and speed up pharmaceutical manufacturing R&D.